A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVEROLIMUS.

Trial Profile

A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVEROLIMUS.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Everolimus
  • Indications Heart transplant rejection
  • Focus Adverse reactions
  • Acronyms ADVANTAGE
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 17 Oct 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 27 Mar 2012 Additional locations identified as reported by as reported by European Clinical Trials Database.
    • 23 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top